Roche Earnings To Rise: Analysts
Make a commentBy Ed Silverman // February 1st, 2007 // 12:01 pm
They cite higher sales of the Herceptin and Avastin, the cancer treatments.
“We believe the operating margin in pharmaceuticals could surprise on the upside, leading to an earnings upgrade,” analysts at bank Vontobel, which maintains its outperform rating on Roche, said in a note cited in this Reuters report. “We forecast another strong Q4 2006 sales performance from Roche Pharmaceuticals.”
Roche shares are up about 7 percent this year.[tags]Roche[/tags]